A Phase I Dose-Escalation Study of Imatinib Mesylate (Gleevec/STI571) plus Capecitabine (Xeloda) in Advanced Solid Tumors

AIM: To determine the maximally tolerated dose, recommended phase II dose and toxicity profile of capecitabine plus imatinib mesylate combination. PATIENTS AND METHODS: Twenty-four patients with advanced solid tumors were treated with capecitabine twice daily on days 1–14 and imatinib mesylate once...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Dugan, Elizabeth, Truax, Roxanne, Meadows, Kellen L., Nixon, Andrew B., Petros, William P., Favaro, Justin, Fernando, Nishan H., Morse, Michael A., Blobe, Gerard C., Hurwitz, Herbert I.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4103189/
https://ncbi.nlm.nih.gov/pubmed/20530436
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki